CClinicalTrials.gg
CompletedNCT03882450Updated Apr 14, 2020

Universal Screening for Vocal Fold Motion Impairment in Children Undergoing Congenital Cardiac Surgery

An interventional study of Flexible fiberoptic laryngoscopy and Laryngeal ultrasonography in Vocal Fold Palsy, Dysphagia and Congenital Heart Disease in Children, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-04-14.

Sponsored by Emory University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Non-randomized
Ages
Up to 18 Years
Sex
All
01

Study summary

The purpose of this study is to determine how often heart or chest surgery in children leads to problems with the movement of the vocal folds.

Read the detailed description

Pediatric vocal fold motion impairment (VFMI) is a well-known cause of dysphonia and dysphagia. Previous studies have demonstrated the most common etiology for pediatric VFMI is cardiothoracic surgery which is possibly due to a variety of mechanisms.The investigators hypothesize that universal screening of neonates for VMFI following congenital cardiac surgery (CCS) will lead to a more accurate incidence and earlier diagnosis of VFMI. They believe that earlier identification will lead to changes in feeding regimens that may decrease length of stay (LOS), decrease time to oral feeding, earlier otolaryngologic intervention if indicated, and decreased rates of readmission for pulmonary or feeding complications. The investigators will also use this information to design a refined algorithm for targeted screening of patients who are more likely to have VFMI based on patient and surgery characteristics.

02

Conditions studied

  • Vocal Fold Palsy
  • Dysphagia
  • Congenital Heart Disease in Children
03

In context

Vocal Cord Paralysis

55 studies on the registry are indexed under Vocal Cord Paralysis; 14 are open to participants now.

This study's enrollment of 94 is above the median of 39 across 38 interventional studies indexed under Vocal Cord Paralysis.

Browse Vocal Cord Paralysis studies →

Lead sponsor

Emory University is the lead sponsor of 1,386 studies on the registry; 236 are open to participants now.

Of its 229 completed or terminated interventional studies of FDA-regulated products, 174 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children 18 and younger with congenital cardiac disease necessitating surgery
  • Children 18 and younger whose parents have given and signed an informed consent and HIPAA Authorization as well as the assent of the patient

Exclusion criteria

Exclusion Criteria:

  • History of prior cardiac surgery
  • Known history of VFMI prior to evaluation
  • Children 18 and younger who do not survive the immediate postoperative course will be excluded.
  • Further exclusion may be determined at the discretion of the Principal Investigator.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • No intervention
    Neonates with congenital cardiac disease (retrospective)

    Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.

  • Active comparator
    Neonates with congenital cardiac disease (prospective)

    Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.

    Procedure: Flexible fiberoptic laryngoscopy · Procedure: Laryngeal ultrasonography

Interventions

  • ProcedureFlexible fiberoptic laryngoscopy

    Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.

  • ProcedureLaryngeal ultrasonography

    Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.

06

What researchers measure

Primary outcomes

  1. Postoperative length of stay (retrospective)

    The number of days of postoperative stay in the hospital will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.

    Time frame: Baseline

  2. Number of readmissions related to feeding difficulty (retrospective)

    The number of readmissions to the hospital for feeding difficulties will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.

    Time frame: Baseline

  3. Number of readmissions related to aspiration (retrospective)

    The number of readmissions to the hospital for aspiration will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.

    Time frame: Baseline

  4. Time to initiation of feeding therapy (retrospective)

    The average time (in days) to start feeding therapy will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.

    Time frame: Baseline

  5. Number of participants with vocal fold motion impairment (prospective)

    The number of study participants diagnosed with VFMI following CCS universal screening will be recorded.

    Time frame: Baseline

  6. Postoperative length of stay (prospective)

    The number of days of postoperative stay at the hospital will be recorded.

    Time frame: Up to 180 days

  7. Time to initiation of feeding therapy (prospective)

    The number of days to start feeding therapy will be recorded.

    Time frame: Day 7

  8. Number of readmissions related to aspiration (prospective)

    The number of readmissions to the hospital for aspiration will be recorded.

    Time frame: 3 months, 6 months, 12 months

  9. Number of readmissions related to feeding difficulty (prospective)

    The number of readmissions to the hospital for feeding difficulties will be recorded.

    Time frame: 3 months, 6 months, 12 months

07

Study locations

1 site
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03882450
Lead sponsor
Emory University
Responsible party
Nikhila Raol (Assistant Professor, Emory University) — Principal investigator
First posted
Mar 20, 2019
Start date
Jan 1, 2019
Primary completion
Mar 13, 2020
Completion
Mar 13, 2020
Last update
Apr 14, 2020

Study contacts

Nikhila Raol, MD, MPH
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion